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Dementia is a decline in mental ability severe enough to interfere with daily life 
functioning. One of the most commonly encountered forms of dementia is Alzheimer’s 
disease (AD) accounting for 60 to 80% of the cases. AD is characterized by aggregation of 
amyloid plaques (Abeta) and neurofibrillary tangles (tau) in the brain leading to memory loss 
and spatiotemporal confusion. Worldwide evidence reveals that 6% of the population over the 
age of 65 and 35% of those over 85 are affected. In real numbers, it is estimated that in 2025 
7.1 million people will be affected by the disease. As the proportion of elderly persons  is 
predicted to increase dramatically in the next decades, AD is estimated to affect 13.8 million 
in 2050 (1). AD and other types of dementia impose a burden not only for the patients, but for 
society as a whole. Important financial resources are spent every year for the caregiving of the 
patients. The total health care cost for all individuals with AD and other dementias is 
estimated at $277 billion in 2018, while this cost is expected to exceed $1 trillion in 2050. 
Additionally, caregivers and relatives of the patients report high emotional stress and exhibit 
increased risk for depression. As a result therapeutic interventions that could even modestly 
alleviate the cognitive deficits would have a major public health benefit. Since AD was first 
described in 1906, there is an abundance of ongoing research aiming to understand the 
underlying mechanism of the disease and to propose possible therapeutic interventions (2). 
Despite the extensive scientific research there is no cure for the disease and the commercially 
available treatments to date have limited efficacy and several side effects. The significance of 
the present dissertation is imprinted in its foremost goal to contribute to the better 
understanding of molecular mechanisms underlying memory formation, and additionally 
identify a possible mechanism leading to protection against memory impairment induced by 
tau pathology. An effective therapeutic strategy for combating the cognitive decline observed 
in the disease would have a great impact on the patients’ quality of life.  
In chapter 4 we examined the molecular basis underlying the cognitive enhancing 
action of drugs that act on the cyclic adenosine monophosphate (cAMP) and cyclic guanosine 
monophosphate (cGMP) signaling cascades. Although upregulation of cyclic nucleotide 
signaling cascades was shown to be promising in alleviating memory decline characterizing 
dementias (3), the mechanistic basis of their effects are largely unknown. In the present thesis 
we showed that upregulation of cGMP pathway during different mnemonic phases is related 
to increased surface levels of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPA) receptors; one of the main excitatory receptors contributing to 
neurotransmission. However, the pro-cognitive effect of upregulating the cAMP pathway was 
not depicted through changes in AMPA receptor dynamics; neither trafficking nor synthesis. 
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These findings suggest that although the cAMP and cGMP pathways converge in several 
common downstream effectors and their upregulation results in a similar behavioral output, 
the mechanistic basis of their cognitive enhancing action is disparate. This observation 
contributes significantly to the better comprehension of the signaling pathways governing 
memory formation and could have important implications in therapeutic interventions 
targeting the cyclic nucleotide cascades.  
In both chapter 5 and 6, we examined the pro-cognitive action of agents that act on the 
nitrinergic and cyclic nucleotide pathways against tau pathology. The innovative aspect of 
both chapters is that we utilized exogenously applied tau oligomers for modeling memory 
impairments encountered in tauopathies. Tau oligomers have recently emerged as one of the 
underlying causes inducing neuronal loss and memory deficits at the early onset of AD, 
before the appearance of other pathological hallmarks. Importantly, we showed that 
pharmacological agents that upregulate nitrinergic or the cyclic nucleotide signaling could 
compensate for oligomeric tau-induced impairments of synaptic strengthening and 
consequently memory formation. In addition, the cognitive enhancing action was mediated by 
an increase in plasticity markers that have been consistently shown to be downregulated in 
AD, like cAMP response element-binding protein (CREB) and AMPA receptors. Our results 
could also be extended to other disorders that are characterized by tau pathology including 
corticobasal degeneration, supranuclear palsy and fronto‐temporal dementia with 
Parkinsonism linked to chromosome 17. Although each of the above disorders has an unique 
biochemical signature related to tau aggregates, they are all characterized by increased tau 
phosphorylation and formation of tau oligomers (4). 
An important aspect of all the chapters is that, among other agents for upregulating the 
cAMP and cGMP signaling pathways, we utilize phosphodiesterase (PDE) inhibitors that 
have been studied both at the preclinical and clinical level for their therapeutic properties. The 
currently approved pharmacological treatments for AD act either on the cholinergic system by 
prolonging the procognitive action of the neurotransmitter acetylcholine in the synapse or in 
the glutamatergic system by reducing neurotoxicity due to the excessive activation of N-
Methyl-D-aspartic acid (NMDA) receptors. The low efficacy and the severe side effects of 
these treatments impose a need for the development of new therapeutic strategies.  
Several cAMP-specific PDE4 inhibitors have been tested in clinical trials up to Phase 
II for their cognitive enhancing action. However, the results of those trials have not yet been 
disclosed (5, 6). The highly potent PDE4 inhibitor roflumilast, that we showed in chapter 6 to 
compensate against tau-induced plasticity and memory impairments, is already on the market 
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under the name Daxas or DailyResp for the treatment of Chronic Obstructive Pulmonary 
Disease (COPD) (7). Importantly, roflumilast was recently shown to improve several aspects 
of cognition, including memory in healthy volunteers (8) at a dose that is 5 times lower than 
the approved dose for the treatment of COPD. As a result, it is devoid of the common emetic 
side effects of PDE4 inhibitors (5). 
In addition to roflumilast, the cGMP-specific PDE5 inhibitors sildenafil and vardenafil 
are FDA-approved for the treatment of erectile dysfunction with the tradenames Viagra and 
Levitra, respectively, because they induce smooth muscle relaxation of blood vessels. 
Additionally, sildenafil is also commercially available as Revatio for the treatment of 
hypertension of the pulmonary artery. Despite the memory improving action of PDE5 
inhibitors, as reported in animal studies, three clinical studies with healthy volunteers found 
no effect of vardenafil or sildenafil on memory performance after a single dose (9-11). 
Nevertheless, another study showed that chronic administration of the PDE5 inhibitor 
udenafil (Zydena) did improve cognition and executive function. This may suggest that 
therapeutic properties of PDE5 inhibitors require chronic treatment to be induced (12). 
Additionally, PDE5 inhibitors exhibit a safe pharmacological profile since their side effects in 
humans are mild and have only been reported by a minority of users (13). Having said this, 
further work and development of PDE5 inhibitors with optimized pharmacokinetic properties 
for CNS delivery is needed before their utilization as a treatment in neurodegenerative 
disorders (14). In that respect, our findings in chapter 4 and 5 contribute to the current 
knowledge regarding the action of PDE5 inhibitors ex vivo and in vivo, by showing the 
molecular mechanism responsible for their pro-cognitive action and providing first evidence 
of their neuroprotective action against tau pathology.  
We acknowledge that all the studies presented in the current thesis have been 
conducted in rodents and do not provide direct evidence for clinical efficacy on the read-out 
parameters of the drugs as described above. Although animal experiments are not always 
translatable to humans, animal research still represent one of the initial and integral steps of 
scientific research into pathophysiological mechanisms and how to combat them. We hope 
that our results will inspire further interest into the development and eventual clinical testing 
of drugs that act in the cyclic nucleotide pathways, while hopefully demonstrating their 
therapeutic potential in memory-related disorders.  
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